Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab β¦ (NCT06943235) | Clinical Trial Compass
RecruitingPhase 2
Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
China60 participantsStarted 2025-04-25
Plain-language summary
ADRIATIC study explored the benefits of immune maintenance therapy after LS-SCLC radiotherapy and chemotherapy. In the presence of immunotherapy, is it necessary to increase the dosage of radiotherapy and can it further improve the efficacy? This study aims to explore the efficacy and safety of simultaneous integrated boost hyperfractionation radiotherapy combined with probiotics and Adalberg monoclonal antibody consolidation therapy for small cell lung cancer.
Who can participate
Age range18 Years β 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
β. Sign written informed consent before implementing any experimental procedures;
β. Age range: 18-80 years old;
β. Pathological diagnosis of small cell lung cancer;
β. Limited stage;
β. ECOG PS 0-1οΌ
β. Receive β€ 2 rounds of chemotherapy or chemotherapy plus immunotherapy;
β. Expected survival time\>3 months;
Exclusion criteria
β. Progress after 2 induction treatments;
β. Severe emphysema, interstitial changes in the lungs, COPD patients;
β. Resting blood oxygen\<93;
β. Have a history of other malignant tumors and have received chemotherapy in the past 3 years;
What they're measuring
1
one year progression free survival rate
Timeframe: one year
2
Complete response rate at the end of radiotherapy for one month
Timeframe: at the end of radiotherapy for one month